Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T04394
(Former ID: TTDR00370)
|
|||||
| Target Name |
Vasopressin receptor (VR)
|
|||||
| Synonyms |
Human vasopressin receptor
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Acute diabete complication [ICD-11: 5A2Y] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
| 1 | Desmopressin | Drug Info | Approved | Diabetic complication | [2], [3], [4] | |
| Clinical Trial Drug(s) | [+] 3 Clinical Trial Drugs | + | ||||
| 1 | BAY 86-8050 | Drug Info | Phase 1 | Heart failure | [5] | |
| 2 | BR6819 | Drug Info | Phase 1 | Heart failure | [6] | |
| 3 | SKF-105494 | Drug Info | Phase 1 | Diuretic vasodilator | [7], [8], [9] | |
| Discontinued Drug(s) | [+] 1 Discontinued Drugs | + | ||||
| 1 | F-992 | Drug Info | Terminated | Urinary incontinence | [10] | |
| Mode of Action | [+] 3 Modes of Action | + | ||||
| Modulator | [+] 3 Modulator drugs | + | ||||
| 1 | Desmopressin | Drug Info | [1] | |||
| 2 | BAY 86-8050 | Drug Info | [11] | |||
| 3 | SKF-105494 | Drug Info | [8], [9] | |||
| Antagonist | [+] 1 Antagonist drugs | + | ||||
| 1 | BR6819 | Drug Info | [6] | |||
| Agonist | [+] 1 Agonist drugs | + | ||||
| 1 | F-992 | Drug Info | [12] | |||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90. | |||||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2182). | |||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
| REF 4 | ClinicalTrials.gov (NCT00748072) 1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy. U.S. National Institutes of Health. | |||||
| REF 5 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035638) | |||||
| REF 6 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 7 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2229). | |||||
| REF 8 | Modulation of vasopressin antidiuretic action by alpha 2-adrenoceptors is species specific. Am J Physiol. 1991 Nov;261(5 Pt 2):R1242-6. | |||||
| REF 9 | Effect of V1/V2-receptor antagonism on renal function and response to vasopressin in conscious dogs. Am J Physiol. 1991 Feb;260(2 Pt 2):F273-82. | |||||
| REF 10 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014040) | |||||
| REF 11 | WO patent application no. 2015,0365,63, Disubstituted trifluormethyl pyrimidinones and use thereof as ccr2 antagonists. | |||||
| REF 12 | A site of tyrosine phosphorylation in the C terminus of the epidermal growth factor receptor is required to activate phospholipase C.. Mol Cell Biol. 1992 January; 12(1): 128-135. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.